Skip to main content

Advertisement

SpringerLink
Log in

Controlled-release doxazosin in the treatment of benign prostatic hyperplasia

  • Paper
  • Published:
Prostate Cancer and Prostatic Diseases Submit manuscript

Abstract

Purpose:

To evaluate the effectiveness and safety of controlled-release doxazosin for benign prostatic hyperplasia (BPH).

Scope:

In this open-label, noncontrolled, observational surveillance study, 3684 men with BPH received 4–8 mg of controlled-release doxazosin gastrointestinal therapeutic system (GITS) for 6 months; 3283 (89.1%) patients completed the trial. Changes in urinary symptoms and quality of life were assessed using the International Prostate Symptom Score (IPSS). Blood pressure and adverse events were assessed.

Conclusion:

After 6 months’ treatment with doxazosin GITS resulted in significant improvements in IPSS. BP was reduced only in hypertensive patients. Doxazosin, GITS was well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Chicharro-Molero JA et al. Prevalence of benign prostatic hyperplasia in Spanish men 40 y old or older. J Urol 1998; 159: 878–882.

    Article  CAS  Google Scholar 

  2. Tsukamoto T et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995; 154 (Part 1): 391–395.

    Article  CAS  Google Scholar 

  3. Sagnier P et al. Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 1994; 151: 1266–1270.

    Article  CAS  Google Scholar 

  4. Berry SJ, Coffey DS, Walsh PC, Ewing LL . The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–479.

    Article  CAS  Google Scholar 

  5. Caine M, Perlberg S, Meretyk S . A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551–554.

    Article  CAS  Google Scholar 

  6. Shapiro A, Mazouz B, Caine M . The alpha-adrenergic blocking effect of prazosin on the human prostate. Urol Res 1981; 9: 17–20.

    Article  CAS  Google Scholar 

  7. Boyle P, Napalkov P . Epidemiology of benign prostatic hyperplasia: current perspectives. Eur Urol 1996; 29 (suppl 1): 7–11.

    Article  Google Scholar 

  8. Grimm RJ et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996; 275: 1549–1556.

    Article  CAS  Google Scholar 

  9. Pool J . Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. Am J Cardiol 1987; 59: 46G–50G.

    Article  CAS  Google Scholar 

  10. Ishimitsu T et al. Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. Hypertens Res 1996; 19: 43–49.

    Article  CAS  Google Scholar 

  11. Chung M et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678–687.

    Article  CAS  Google Scholar 

  12. Roehrborn CG, Kirby R, Prajsner A, Anderson M . A double-blind, placebo-controlled study evaluating the onset of action of doxazosin GITS for the treatment of patients with BPH (Abst 921). J Urol 2004; 171 (suppl): 244.

    Article  Google Scholar 

  13. Kirby RS et al. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. Bri J Urol Int 2001; 87: 192–200.

    Article  CAS  Google Scholar 

  14. Hernandez C et al. Hiperplasia benigna prostatica e hipertension arterial. Eficacia del tratamiento con alfabloqueantes. Urol Integr Invest 1998; 3: 69–73.

    Google Scholar 

  15. Kirby RS . Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995; 46: 182–186.

    Article  CAS  Google Scholar 

  16. Black HR . Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. J Cardiovasc Pharmacol 2003; 41: 866–869.

    Article  CAS  Google Scholar 

  17. Black HR, Sollins JS, Garofalo JL . The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens 2000; 13 (Part 1): 468–474.

    Article  CAS  Google Scholar 

  18. Langdon CG, Packard RS . Doxazosin in hypertension: results of a general practice study in 4809 patients. Br J Clin Pract 1994; 48: 293–298.

    PubMed  CAS  Google Scholar 

  19. Pool JL . Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. Br J Clin Pract Suppl 1994; 74: 8–12.

    PubMed  CAS  Google Scholar 

  20. Carruthers G et al. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. Am J Cardiol 1993; 71: 575–581.

    Article  CAS  Google Scholar 

  21. Langdon C . Doxazosin: a study in a cohort of patients with hypertension in general practice - an interim report. Am Heart J 1991; 121: 268–273.

    Article  CAS  Google Scholar 

  22. McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–2398.

    Article  CAS  Google Scholar 

  23. Kirby RS, Quinn S, Mallen S, Jensen D . Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. Int J Clin Pract 2004; 58: 6–10.

    Article  CAS  Google Scholar 

  24. De Reijke TM, Klarskov P . Comparative efficacy and tolerability of two a1-Adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms due to benign prostatic enlargement. Bri J Urol Int 2004; 93: 757–762.

    Article  CAS  Google Scholar 

  25. Kirby RS, O’Leary M P, Carson C . Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. Bri J Urol Int 2005; 95: 103–109.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The study was funded by a grant from Pfizer Inc.

Author information

Authors and Affiliations

  1. Hospital General Universitario Gregorio Marañón, Madrid, Spain

    C Hernandez, R Duran, J Jara, I Castaño & M Moralejo

Authors
  1. C Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Duran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Jara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Castaño
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Moralejo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Hernandez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hernandez, C., Duran, R., Jara, J. et al. Controlled-release doxazosin in the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 8, 375–380 (2005). https://doi.org/10.1038/sj.pcan.4500820

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500820

  • Springer Nature Limited

Keywords

This article is cited by

Search

Navigation